Inflation and declining FDA drug approvals will pose challenges for pharma contract manufacturers in 2023, stated GlobalData in its latest report – ‘New Drug Approvals and Their Contract Manufacture – 2023 Edition’. The report said that USFDA’s new molecular entity approvals declined substantially in 2022, causing overall New Drug Application (NDA) approvals to drop, which meant fewer commercial-scale production contracts for the most innovative products.
